Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegvisomant versus escitalopram versus placebo for depression in acromegaly
2014-000265-43Phase 4Suspended
- Sponsor
- Max Planck Institute of Psychiatry
- Start
- Nov 2017
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in major depressive disorder (MDD) and acromegaly comparing Pegvisomant arm, Escitalopram arm and Placebo arm (3 arms). Primary endpoint: Change in Beck Depression Inventory-II score. Started Nov 2017; status: suspended.
02
Drugs
pegvisomantescitalopram
03
Conditions
major depressive disorder (MDD)acromegaly
Beyond the preview
Go deeper on 2014-000265-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000265-43.